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Abstract
Introduction: Stem cells have great therapeutic potential due to their capacity for self-renewal and their potential
for differentiating into multiple cell lineages. It has been recently shown that the host immune system has
fundamental effects on the fate of transplanted mesenchymal stem cells during bone repair, where the topical
administration of aspirin is capable of improving calvarial bone repair in rodents by inhibiting tumor necrosis factor-α
(TNF-α) and interferon-γ (IFN-γ) production. This study investigates whether aspirin is capable of accelerating the
regenerative potential of bone marrow mesenchymal stem cells (BMSC) in a mini swine calvarial bone defect model.
Methods: Calvarial bone defects (3 cm × 1.8 cm oval defect) in mini swine were treated with BMSC pretreated
with 75 μg/ml aspirin for 24 h seeded onto hydroxyaptite/tricalcium phosphatel (HA/TCP), or with BMSC with
HA/TCP, or with HA/TCP only, or remained untreated. Animals were scanned with micro-computed tomography
(microCT) at 2 days and 6 months postsurgery and were sacrificed at 6 months postsurgery with decalcified
tissues being processed for histomorphometric examination. The cytokine levels, including TNF-α and IFN-γ, were
measured by enzyme-linked immunosorbent assay (ELISA).
Results: Aspirin at 75 μg/ml promoted the osteogenesis of BMSC in vitro and in vivo, shown by Alizarin Red staining
and new bone volume in the nude mice transplantation model (p < 0.01), respectively. Defects treated with
aspirin-BMSC showed significantly greater new bone fill compared with other three groups at 6 months postsurgery
(p < 0.01). Aspirin-BMSC treatment has significantly decreased the concentration of TNF-α and IFN-γ (p < 0.05).
Conclusions: The present study shows that BMSC pretreated with aspirin have a greater capacity to repair calvarial
bone defects in a mini swine model. The results suggest that the administration of aspirin is capable of improving
BMSC-mediated calvarial bone regeneration in a big animal model.
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Introduction
Adult or mesenchymal stem cells (MSC) are plastic adher-
ent stromal cells found in special tissues and organs of
human adults. With the capacity for self-renewal and
multi-lineage differentiation, they are considered a prom-
ising cell source for tissue engineering, as they are easily
accessible and not associated with ethical issues in relation
to their use [1–5]. It has been widely accepted that MSC-
based therapy has shown significant improvement of tis-
sue regeneration in pre-clinical models and clinical trials.
Despite the recent progress in MSC-based tissue regener-
ation in the last few decades, a major challenge remains
how to restore new bone formation following disease or
insult with the high quality and the bone volume that
meet the needs of the body [6–9].
Recently, considerable interest has developed that the
host immune imbalance accounts for, at least in part,
the imbalance in bone remodeling that occurs in various
bone disorders, such as arthritis and periodontitis, al-
though microbial infection is thought to be one of the
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dominant factors in the initiation of periodontitis. As the
immune imbalance might be one of the major factors in
initiating the previously mentioned diseases, studies have
been conducted aiming to manipulate the immune system
of susceptible individuals. Studies have been carried out to
investigate the interactions of MSC and the host immune
system. Compared with embryonic stem cells, MSC have
been shown to be low immunogenic, thus allogeneic MSC
are able to escape the immune surveillance of the body
and contribute to tissue regeneration [10–12]. On the
other hand, we have recently shown that the host immune
system has fundamental effects on the fate of transplanted
MSC during bone remodeling, where TNF-α and IFN-γ
produced by proinflammatory T cells play a critical role
[13–15]. Intriguingly, the topical administration of aspirin,
alternatively the systemic infusion of regulatory T cells, is
capable of inhibiting TNF-α and IFN-γ production and,
therefore, improve calvarial bone repair in rodents [13].
Compared with the systemic infusion of regulatory T cells,
the topical administration of aspirin has more advantages
from the safety aspects, since aspirin has been used as a
non-steroidal anti-inflammatory agent (NSAID) for de-
cades with a known side-effect profile. Moreover, the use
of aspirin at the sites of tissue damage is less technically
challenging than the systemic infusion of regulatory T cells
and, therefore, can be easily accepted by clinical practi-
tioners and patients.
Aspirin has recently been shown to regulate the bal-
ance between bone resorption and bone formation in
ovariectomized-induced osteoporosis [16] and to accel-
erate bone repair in rodents [10]. It is imperative to in-
vestigate the safety and efficacy of aspirin-pretreated
BMSC in a big animal model before clinical trials are
initiated. In the present study, we examined whether
aspirin-pretreated BMSC is capable of accelerating the




A total of 14 miniature pigs were used in the present
study. Twelve inbred male miniature pigs (for calvarial
defect surgery, 12 months of age) and two inbred female
miniature pigs (for cell culture, three to four months of
age) were supplied by the Institute of Animal Science of
the Chinese Agriculture University (Beijing, China) and
housed under conventional conditions. The study was
conducted following the approved guidelines set by the
Animal Ethics Committee of the School of Stomatology,
Capital Medical University (Beijing, China). All animal
experiments were performed under the institutionally
approved protocols for the use of animal research (Capital
Medical University # 2012-x-53).
Isolation and culture of mini swine BMSC
Bone marrow aspirates were obtained from the posterior
iliac crest of two inbred female mini swine under the ap-
proved guidelines set by the Animal Ethics Committee of
the School of Stomatology, Capital Medical University
(Beijing, China). Bone marrow mononuclear cells were
prepared as described previously [17]. Primary bone
marrow-derived mesenchymal stem cell (BMSC) cultures
were established in tissue culture flasks and maintained in
the cell growth medium. The cell growth medium con-
tained alpha minimum essential medium (α-MEM, Invi-
trogen, Carlsbad, CA, USA.) supplemented with 10 % fetal
calf serum, 100 μM L-ascorbic acid 2-phosphate, 2 mM L-
glutamine (Biosource, Invitrogen), 100 U/ml penicillin
and 100 μg/ml streptomycin in a humidified atmosphere
(37 °C, 5 % CO2).
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Flow cytometric analysis
Flow cytometric analysis was performed as previously de-
scribed [18]. Briefly, swine BMSC at passage three, treated
with or without 75 μg/ml aspirin for 24 h, were de-
tached and incubated with primary antibodies, includ-
ing CD146 (MCAM, melanoma cell adhesion molecule)
(BD Biosciences, San Jose, CA, USA), CD90 (THY-1,
Thy-1 cell surface antigen) (BD Biosciences), CD31
(PECAM1, platelet/endothelial cell adhesion molecule 1)
(BD Biosciences), HLA-DR (human leukocyte differenti-
ation antigen class II) (Biolegend, San Diego, CA, USA) or
corresponding isotype-matched control antibodies and
fluorescein isothiocyanate (FITC)-conjugated secondary
antibodies. Samples were washed, fixed with fluorescence-
activated cell sorting (FACS) Fix and analyzed using a flow
cytometer (Calibur, BD, Franklin Lakes, NJ, USA).
Cell differentiation assay in vitro
Osteogenic and adipogenic differentiation assays were per-
formed as previously reported [18, 19]. The calcification
of extracellular matrix and lipid-laden droplets were de-
tected using Alizarin Red and Oil Red O staining, respect-
ively. The gene expressions of Runx2 and osteopontin
were assayed by real time RT-PCR. The cells cultured in
the growth medium (α-MEM supplemented with 10 %
fetal calf serum, 100 μM L-ascorbic acid 2-phosphate,
2 mM L-glutamine and 100 U/ml penicillin/100 μg/ml
streptomycin) were used as the control in the differenti-
ation assay. GAPDH was used as a housekeeping control
gene against which samples were normalized. All mRNA
quantification data represent the mean ± standard error of
the mean (SEM) of triplicate experiments normalized
to the house-keeping gene GAPDH. All mRNA quanti-
fication data are presented as the fold changes in the
expression of the gene of interest in the osteoinductive
conditions to that in the control conditions.
Cell proliferation assay in vitro
The effect of aspirin on swine BMSC proliferation was
assessed using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,
5-diphenyl tetrazolium bromide) assay. Ex vivo expanded
swine BMSC were seeded at passage three (1.0 × 104 cells/
well) in triplicate using a 96-well flat-bottom plate (Costar,
Cambridge, MA, USA) and maintained in 100 μl medium
with aspirin (50, 75, 100, 150 or 200 μg/ml) or standard
culture medium for five days. Cells were treated with
5 mg/ml of MTT reagent (Sigma-Aldrich, St. Louis,
MO,USA) and incubated at 37 °C for 4 h. After cells were
washed twice in PBS and treated with dimethyl sulfoxide,
the absorbance in each well was measured at a wavelength
of 490 nm using an automatic enzyme-linked immuno-
sorbent assay (ELISA) reader (ELx800; BioTek Instru-
ments Inc., Winooski, VT, USA).
Cell growth curve assays
BMSCs were seeded in 60-mm plates at a density of
1.0 × 104 cells/plate for cell growth curve assay. Cells
were counted at 2, 3, 4, 5, and 6 days after seeding. Cells
were digested with 0.25 % trypsin (Invitrogen), resus-
pended in 1 ml PBS and counted with an automated cell
counter (TC10TM, Bio-Rad Laboratories, Hercules,
California USA). An equivalent volume of trypan blue was
added to the cell suspension to exclude nonviable cells.
Alizarin red staining
BMSCs were grown in osteogenic-inducing medium,
which contained the cell growth medium supplemented
with 2 mM β-glycerophosphate, 1.8 mM KH2PO4, and
10 nM dexamethasone. To detect mineralization, cells
were induced for three weeks, fixed with 70 % ethanol,
and stained with 2 % Alizarin Red (Sigma-Aldrich). To
determine calcium content quantitatively, cells stained
with Alizarin Red were destained with 10 % cetylpyridi-
nium chloride in 10 mM sodium phosphate for 30 min
at room temperature. The calcium concentration was
determined by measuring absorbance at 562 nm on a
multiplate reader and comparing the reading to a stand-
ard calcium curve, constructed with calcium diluted in
the same solution. The final calcium level in each group
was normalized to the total protein on centration de-
tected in a duplicate plate [20].
Transplantation of BMSC into immunocompromised mice
Approximately 4.0 × 106 BMSC, treated with or without
75 μg/ml aspirin for two days, were mixed with hydroxy-
apatite/tricalcium phosphate (HA/TCP) ceramic particles
(40 mg; Engineering Research Center for Biomaterials,
Sichuan University, China) as a carrier and subcutaneously
implanted into the dorsal surface of eight- to ten-week-old
immunocompromised mice. Xenogenic transplants were
harvested at week 8 and stained with hematoxylin and
eosin (H & E) staining before histological sections were an-
alyzed for statistical evaluation.
Generation of mini swine calvarial bone defect and
transplantation of BMSC to the calvarial bone defect
The present study was performed under the approved
guidelines of the Ethics Committee of the School of
Stomatology, Capital Medical University, Beijing. The
calvarial bone defect was created as previously described
[21, 22]. Twelve inbred male miniature pigs (12 months
of age) were supplied for calvarial defect surgery. Two
oval defects (3 cm × 1.8 cm) were created in each animal;
a total of 24 calvarial defects were generated in 12 mini-
ature pigs. The defects were randomly assigned to four
different groups and treated as following (six defects per
group): (1) BMSC (1.0 × 106) treated with 75 μg/ml
aspirin for 24 h using HA/TCP as carrier, were
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transplanted into calvarial defects; (2) BMSC (1.0 × 106)
using HA/TCP as carrier, were transplanted into calvar-
ial defects; (3) calvarial defects were filled with 40 mg
HA/TCP only; and (4) calvarial defects were filled with
nothing. The bone defects were then covered with ab-
sorbable gelatin sponges (Jinling Pharmaceutical CO.,
LTD, Nanjing, China). The defects that were filled with
HA/TCP + BMSC treated with 75 μg/ml aspirin were
covered with absorbable gelatin sponges with 75 μg/ml
aspirin, while other groups were covered with absorbable
gelatin sponges only. According to the manufacturer, the
gelatin sponge is fully absorbed within four to six weeks.
Evaluation of the release of aspirin in the gelatin sponge
To evaluate the kinetics of aspirin release, we analyzed
the concentration of aspirin and its product of metabol-
ism, salicylic acid, in absorbable gelatin sponge at differ-
ent time points. Aspirin (100113–201405, 99.8 % purity),
salicylic acid (100106–201104, 99.9 % purity) and tinida-
zole [100336–200703, 99.9 % purity, internal standard
(IS)] were purchased from National Institutes for Food
and Drug Control (Beijing, China), HPLC grade metha-
nol, acetonitrile, and trifluoroacetic acid were purchased
from Thermo Fisher Scientific (Waltham, MA, USA).
Ultrapure water was obtained from a Milli-Q water puri-
fication device (Millipore, Bedford, MA, USA). Chroma-
tographic analysis was performed on a Dionex Ultimate
U3000 chromatographic system (Waltham, MA, USA).
Data were acquired and processed using Chromeleon
software (version 7.0). Briefly, the implanted absorbable
gelatin sponges with aspirin were removed from surgery
sites and collected into 1.5 ml eppendorf tubes at differ-
ent time points. The absorbable gelatin sponges were
weighed before being cut into small pieces and then
200 μl methanol was added to extract the drugs and pre-
cipitate the protein. The mixture was vortex mixed for
one min, ultrasonic dissolved for one min, centrifuged at
10,000 × g for two min, then 100 μl of the supernatant
was mixed with 10 μl IS, vortex mixed for one min, cen-
trifuged at 10,000 × g for two min, and then 20 μl of the
supernatant was injected into the HPLC system. Chro-
matographic separation was achieved using Acclaim™
C18 column (150 × 4.6 mm, 5 μm particles, Thermo Sci-
entific). Isocratic elution consisted of acetonitrile and
water (28:72) (both contain 0.05 % trifluoroacetic acid).
The flow rate was 1.0 ml/min, the injection volume was
20 μl and the oven temperature was set at 30 °C. As-
pirin, salicylic acid and tinidazole were measured at
277 nm using a diode array detector.
Quantitative and histological evaluation of regenerated
bone
The calvarial bone samples were harvested at six months
postsurgery. Bone specimens were fixed in 10 % buffered
formalin. The specimens were decalcified and embedded
in paraffin. Sections of 5- to 6-μm thickness from the em-
bedded specimen were stained with H & E, Masson’s tri-
chrome or methylene blue in the Institute of Dental
Research, General Hospital of Chinese PLA (Beijing,
China). The volume of newly-formed bone within each
section was analyzed semi-quantitatively by histomorpho-
metric techniques.
Masson’s trichrome staining was performed according to
the manufacturer’s protocol (Cat No.26386, Electron
Microscopy Science, Hatfield, PA, USA). Briefly, tissue sec-
tions were deparaffinized, stained with Bouin’s Fluid solu-
tion, cooled and washed in running tap water until the
yellow color disappeared. The sections were then placed in
Weigert’s hematoxylin, stained with Biebrich scarlet-acid
fuchsin solution and washed in distilled water. The sec-
tions were placed in phosphomolybdic-phosphotungstic
acid solution until the collagen was decolorized, before
they were transferred directly (without rinse) to the aniline
blue solution and washed with 1 % acetic acid. With this
method, blue staining indicates regenerated bone, osteoid
or collagen fibers, while red staining indicates mature bone
and orange staining indicates erythrocyte.
Cytokine levels in mini swine calvarial bone tissues
The cytokine levels in the implants were measured by
ELISA [13]. The implants of BMSC mixed with HA-TCP
ceramic particles were harvested at day 30 after transplant-
ation into calvarial bone defects. The cytokine concentra-
tions, including TNF-α and IFN-γ (Invitrogen, Carlsbad,
Canada), in the calvarial bone tissues were measured using
a commercial ELISA kit according to the instructions of
the manufacturer.
Bone analysis by micro-computed tomography
Analysis was conducted as previously described. 3D
microarchitecture of the calvarial bone samples was evalu-
ated using micro-computed tomography (microCT) (110
kv, 19 mA) two days and six months postsurgery. The
newly-formed bone density and bone thickness were mea-
sured and compared between different groups.
Statistical analysis
Data analysis was carried out using SPSS10 statistical soft-
ware. Data points are reported as the mean ± standard de-
viation (SD) or mean ± standard error of the mean (SEM).
Statistical significance of (*) p ≤ 0.05 was determined using
the unpaired Student t-testor one-way analysis of variance
(ANOVA). Statistical analysis was performed as described
using at least three biological replicates unless otherwise
stated.
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Results
Isolation and characterization of BMSC
To confirm the differentiation potential of swine BMSC,
ex vivo expanded BMSC were subjected to osteogenic
and adipogenic inductive culture conditions for four
weeks. Alizarin Red-positive mineral nodules and Oil
Red O-positive fat-laden droplets were formed in osteo-
genic and adipogenic culture conditions, respectively
(data not shown).
Aspirin has no effect on the immunophenotype of swine
BMSC
To examine whether aspirin treatment affects the cell
surface marker profile of BMSC, cells were treated with
75 μg/ml aspirin for 24 h before their immunophenotype
was investigated using flow cytometry. Aspirin-treated
swine BMSC had a compatible cell surface expression
pattern with untreated cells (data not shown), which
showed negativity for an endothelial cell surface marker,
CD31 (platelet endothelial cell adhesion molecule-1/
PECAM-1) and high positivity for CD90 (cell surface
markers associated with stem cells). Aspirin treatment
did not affect the cell surface expression of STRO-1
(early mesenchymal stem cell marker) (data not shown).
The effect of aspirin on BMSC proliferation
BMSC were treated with aspirin at various concentrations
(50, 75, 100, and 150 μg/ml) before the rate of cell prolifera-
tion was examined with the MTTassay. Aspirin at 75 μg/ml
was shown to enhance BMSC proliferation (Fig. 1a).
Aspirin at high concentrations (100 and 150 μg/ml)
seemed to display an inhibitory effect on cell prolifer-
ation but these results were not statistically significant
(Fig. 1a). The cell growth curve assay also confirmed
that aspirin at 75 μg/ml enhanced BMSC proliferation
(Fig. 1b).
Aspirin stimulates the osteogenesis of BMSC in vitro and
in vivo
We next explored whether aspirin treatment would pro-
mote the osteogenic potential of swine BMSC. As shown
in Fig. 2a, when BMSC were subjected to osteogenic in-
ductive conditions, aspirin treatment at concentrations
of 50, 75, 100, 150, and 200 μg/ml increased the capabil-
ity of forming Alizarin red-positive calcified deposits.
This was confirmed by the up-regulation of bone-related
genes (Runx2 and osteopontin) after BMSC were treated
with 75 μg/ml aspirin in osteoinductive conditions for
two weeks (Fig. 2b) (P < 0.05).
To investigate the effect of aspirin treatment on the
mineral forming capacities of swine BMSC in vivo, using a
“gold standard” for assessing stem cell characteristics,
BMSC treated with 75 μg/ml aspirin or untreated cells
were transplanted into immunocompromised mice using
HA/TCP as a carrier and samples were recovered at week
8. Aspirin treatment significantly stimulated BMSC-
mediated bone formation in nude mice as shown in Fig. 2c,
d, and e (p < 0.05). These data collectively indicate that as-
pirin at the concentration of 75 μg/ml promotes BMSC-
based mineral formation both in vitro and in vivo.
Aspirin promotes BMSC-based calvarial bone regeneration
in mini swine
As aspirin is capable of promoting the osteogenesis of
BMSC, we hypothesized that aspirin treatment, together
with BMSC, might improve the healing process of calvar-
ial bone defects in mini swine. Calvarial bone defects were
freshly created in mini swine (Fig. 3a-d) before they were
filled with nothing, HA/TCP, or HA/TCP + BMSC treated
with or without 75 μg/ml aspirin for 24 h. To investigate
whether aspirin treatment has any potential side effects
on biochemistry values in mini swine, whole blood
samples were collected for biochemical testing. Data illus-
trated that aspirin treatment did not significantly alter the
biochemistry profile of mini swine (data not shown),
Fig. 1 Aspirin at 75 μg/ml enhances BMSC proliferation. Aspirin at 75 μg/ml enhanced BMSC proliferation, while aspirin at high concentrations
displayed an inhibitory effect on cell proliferation, shown by MTT assay a. The cell growth curve assay showed that aspirin at 75 μg/ml enhanced
BMSC proliferation b. The results are representative of at least three independent experiments. Results are expressed as mean ± standard deviation (SD)
and statistical significance is shown as (*) p < 0.05 or (**) p < 0.01. BMSC bone marrow mesenchymal stem cells
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suggesting the safety of using aspirin-treated BMSC for
promoting bone formation in vivo. Experiments on the
kinetics of aspirin release in the absorbable gelatin sponge
have shown that aspirin or salicylic acid could almost not
be detected after 3 h (Additional file 1: Figure S1).
Two days postsurgery, the operative defects could be
easily identified in microCT images showing the margin
of the defects (Fig. 3e-h). At six months following sur-
gery, the margin of the defects was not clearly identifi-
able as the formation of mineralized tissue (Fig. 3i-l).
Quantitative examination of microCT images illustrated
that at the six-month time point, the untreated group
showed significantly lower new bone density than the
other three groups (p < 0.05), while the HA/TCP +
BMSC-aspirin group did not show higher new bone
density than the HA/TCP+BMSC or HA/TCP group
(Fig. 3m).
When calvarial bone specimens were retrieved 12 months
postsurgery, minimal formation of mineralized tissues was
observed in the untreated group (Fig. 4a), while limited
new bone generation was noted in the HA/TCP group
(Fig. 4b). A greater degree of bone-like tissue formation
was noted in defects treated with HA/TCP+BMSC-aspirin
(Fig. 4d), compared with those treated with HA/TCP
+BMSC (Fig. 4c).
Calvarial bone specimens were retrieved and sections
were sent for histological examination using H&E
(Fig. 4e-l), Masson’s trichrome (Fig. 5a-h) or methylene
blue staining (Fig. 5i-p). Images were captured at the
lower magnification showing the whole defect area
(Figs. 4e-h, 5a-d and 5i-l). Untreated defects appear to be
filled with fibrous tissue with minimal bone formation
(Figs. 4e, 5a, and 5i), while HA/TCP-treated defects ex-
hibit formation of moderate amount of mineralized tissues
(Figs. 4f, 5b, and 5j). The HA/TCP+BMSC-aspirin group
displayed almost full restoration of the defect (Figs. 4h, 5d
and 5l), with improvement of formation of newly-formed
bone compared to the control HA/TCP+BMSC group
(Figs. 4g, 5c and 5k). At higher magnification (Figs. 4i-l,
5e-m, and 5m-p), untreated defects were filled with fi-
brous tissue (Figs. 4i, 5e and 5m), while limited new bone
formation was noted in the HA/TCP group (Figs. 4j, 5f
and 5n). A moderate amount of newly-formed bone was
noted in defects treated with HA/TCP+BMSC (Figs. 4k,
Fig. 2 Aspirin stimulates the osteogenesis of BMSC in vitro and in vivo. BMSC treated with different concentrations of aspirin increased the
capability of forming Alizarin red-positive calcified deposits a. BMSC treated with 75 μg/ml aspirin showed the up-regulation of bone related
genes (Runx2 and osteopontin) b. Aspirin treatment significantly stimulated BMSC-mediated bone formation in immunocompromised mice
transplants c-e. The results are representative of at least three independent experiments. Results are expressed as mean ± standard deviation (SD)
and statistical significance is shown as (*) p < 0.05 or (**) p < 0.01. Scale bars = 100 μm. B bone, HA hydroxyapatite/tricalcium phosphate, CT
connective tissues, BMSC bone marrow mesenchymal stem cells
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5g, and 5o). The HA/TCP+BMSC-aspirin group demon-
strated formation of an abundant amount of mineralized
tissue (Figs. 4l, 5h, and 5p). The presence of HA/TCP par-
ticles was also noted. Semi-quantitative analysis of the per-
centage of new bone formation showed that the HA/TCP
+ BMSC-aspirin group demonstrated a statistically higher
percentage of mineralized matrix formation at the regen-
erated defect site (71.6 ± 5.77 %) compared with the HA/
TCP + BMSC group (55.0 ± 4.08 %), the HA/TCP group
(43.3 ± 5.75 %), or the control group (26.6 ± 5.75 %) (n = 6
in each group) (P < 0.01) (Fig. 4m).
Aspirin treatment reduced the concentration of
proinflammatory cytokines in calvarial bone defects
As we have recently reported that BMSC-mediated bone
formation is negatively correlated with the concentrations
of TNF-α and IFN-γ [13], we investigated the concentra-
tion of TNF-α and IFN-γ in mini swine calvarial bone
defects. Aspirin pretreatment significantly decreased the
concentration of TNF-α (Fig. 6a) and IFN-γ (Fig. 6b) com-
pared to the HA/TCP-BMSC group (p < 0.05), while
BMSC treatment significantly reduced the concentration
of IFN-γ in the calvarial bone defect (Fig. 6b) (P < 0.05)
but not that of TNF-α (Fig. 6a).
Discussion
Although MSC-based therapy has shown promising out-
comes of tissue regeneration in pre-clinical models and
clinical trials in the last few decades, a major challenge
remains how to restore new bone formation following
disease or insult with the high quality and bone volume
that meet the needs of the body. The present study is, to
our knowledge, the first report that the administration
of aspirin, coupled with bone marrow-derived mesen-
chymal stem cells, is capable of promoting bone repair
in a big animal model. In addition, aspirin has been used
as a non-steroidal anti-inflammatory drug (NSAID) for
decades with a known side-effect profile. Therefore, the
topical administration of aspirin holds greater advan-
tages from the safety perspective, compared with other
strategies to promote the osteogenesis of stem cells, such
as the systemic infusion of regulatory T cells, the use of
genetically modified cells and the treatment of stem cells
with growth factors. Collectively, the present study sheds
Fig. 3 Aspirin promotes BMSC-based calvarial bone regeneration in mini swine shown by microcomputed tomography (microCT) images. Two
freshly created calvarial bone defects were created in each mini swine before they were filled with nothing, HA/TCP, HA/TCP + BMSC treated with
or without 75 μg/ml aspirin a-d. MicroCT images of calvarial defect areas were captured two days e-h and six months postsurgery i-l, showing new
bone generation in the untreated group e and i, HA/TCP group f and j, HA/TCP + BMSC g and k and HA/TCP + BMSC-aspirin h and l. Quantitative
examination of microCT images illustrated relative new bone density between different groups six months postsurgery m. Results are expressed as
mean ± standard deviation (SD) and statistical significance is shown as (*) p < 0.05 or (**) p < 0.01. BMSC bone marrow mesenchymal stem cells, HA/TCP
hydroxyapatite/tricalcium phosphate
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light on the therapeutic effects of aspirin-treated MSC in
a big animal model and encourages clinical trials for
bone-related disorders, such as bone fractures, periodon-
titis, arthritis, and orofacial deformity.
Aspirin (acetylsalicylic acid or salicylic acid) is a NSAID
drug that has been widely used for a variety of clinical ap-
plications, such as to relieve pain, to reduce fever and
inflammation, to treat and prevent common cardiovascu-
lar disorders, such as heart attacks and strokes, and as an
anti-inflammatory medication. Due to its involvement in
multiple biological pathways, aspirin may have as-yet-
unknown benefit(s) in a variety of conditions that deserve
further investigation [23–26].
Studies have been focused on the roles of aspirin in the
process of bone metabolism for the last decade. Epidemio-
logic studies revealed that current aspirin users had
significantly higher bone mineral density compared with
non-users according to quantitative computed tomography
data [23]. A recent study has highlighted the positive effect
of aspirin in the treatment of ovariectomy-induced
osteoporosis through activating osteoblasts by increas-
ing telomerase activity and inhibiting osteoclasts [16].
Due to its involvement in multiple biological path-
ways including inhibiting cyclo-oxygenase-1 (COX-1),
COX-2 and prostaglandin 2 (PG2), it is very difficult
to identify the exact mechanisms of its roles in bone
remodeling [16]. The underlying mechanisms of the
effect of aspirin on bone metabolism appear to be
correlated with the increased expression of osteogenic
genes including Runx2 (a master gene for osteogenic
differentiation), alkaline phosphatase and osteocalcin
[16]. Additionally, ex vivo aspirin treatment was cap-
able of accelerating degradation of phospho-β-catenin,
resulting in an increased level of WNT signaling, a
recognized pathway in osteogenesis [27].
The present study lends support to the notion that as-
pirin treatment is capable of promoting osteogenesis both
in vitro and in the mice transplantation model. This is
consistent with our previous study showing that aspirin
has a direct positive effect on the bone forming ability of
BMSC [13]. It should be noted that both in vitro tissue
culture and the mice transplantation model represent a
microenvironment in the absence of inflammation or with
low inflammation levels. On the other hand, an inflamma-
tory microenvironment is present in various disease set-
tings, either in an acute or chronic manner, such as
periodontitis, bone fractures and orofacial deformity. This
inflammatory microenvironment has a fundamental impact
Fig. 4 Aspirin promotes BMSC-based calvarial bone regeneration in mini swine. Calvarial bone specimens, treated with nothing a, HA/TCP b, HA/
TCP + BMSC c or HA/TCP + BMSC-aspirin d, were retrieved six months postsurgery. Sections were stained with H&E e-l. Images were captured at
the lower e-h and higher magnification i-l. Semi-quantitative analysis of the percentage of new bone formation between different groups was
based on the results of H&E staining m. The results are representative of at least three independent experiments. Results are expressed as mean ±
standard deviation (SD) and statistical significance is shown as (*) p < 0.05 or (**) p < 0.01. Scale bars = 1 cm in e-h; scale bars = 100 μm in i-l. B bone,
HA hydroxyapatite/tricalcium phosphate, CT connective tissues, BMSC bone marrow mesenchymal stem cells, H & E hematoxylin and eosin
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on the regenerative capacities of both endogenous [28] and
exogenous MSC [13]. It is imperative to investigate the ef-
fect of aspirin pretreatment in a microenvironment with
inflammatory cell infiltration where BMSC osteogenic cap-
acity has been compromised, such as freshly created calvar-
ial bone defects, preferably in a big animal model as in the
present study.
In the present study, absorbable gelatin sponges with
or without aspirin were used to cover the defect area.
We analyzed the concentration of aspirin and salicylic
acid in transplanted HA/TCP at different time points.
However, the concentrations of aspirin and salicylic
acid were too low to be assayed. This may be due to
the fact that the gelatin sponges had been squeezed to
make sure only a limited amount of aspirin was left in
the sponges before the sponges were used to cover the
defect area. This is to minimize the possibility that the
treatment on one side of the animal might interfere
with that on the other side, where the treatment on
both sides of the animal might not be the same. In
other words, this is to avoid aspirin on the experimen-
tal side interfering with the healing of the defects on
the other side. Evaluation of the kinetics of aspirin and
salicylic acid release showed that after 3 h, almost no
aspirin or salicylic acid could be detected in gelatin
sponges. This indicates that the gelatin sponges served
Fig. 6 Aspirin treatment reduced levels of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in mini swine calvarial bone defects. Aspirin pretreatment
significantly decreased the concentration of TNF-α a and IFN-γ b compared to the HA/TCP-BMSC group. BMSC treatment reduced the concentration IFN-γ
in the calvarial bone defect b but not that of TNF-α a. The results are representative of at least three independent experiments. Results are expressed as
mean ± standard deviation (SD) and statistical significance is shown as (*) p< 0.05 or (**) p< 0.01. HA/TCP hydroxyapatite/tricalcium phosphate, BMSC bone
marrow mesenchymal stem cells
Fig. 5 Aspirin promotes BMSC-based calvarial bone regeneration in mini swine shown by histomorphometric analysis. Calvarial bone specimens,
treated with nothing, HA/TCP, HA/TCP + BMSC or HA/TCP + BMSC-aspirin, were retrieved six months postsurgery. Sections were stained with Masson’s
trichrome a-h or methylene blue i-p. Images were captured at the lower a-d and i-l and higher magnification e-h and m-p. Scale bars = 1 cm in a-d
and i-l; scale bars = 100 μm in e-h and m-p. B bone; HA hydroxyapatite/tricalcium phosphate, CT connective tissues, BMSC bone marrow mesenchymal
stem cells
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as a barrier to stabilize the blood clot and transplant-
ation in the defects area in the present study, rather
than for aspirin to be slowly released.
A delicate host-parasite balance is thought to be inter-
rupted in a variety of bone disorders, such as periodontitis
and arthritis. For example, it has been accepted that host
systemic conditions account for, at least in part, the imbal-
ance in bone remodeling in the process of periodontitis,
although the bacterial infection is thought to be one of the
dominant factors. While the current therapeutic strategy
for the management of periodontitis, scaling and root
planing, is based on documented scientific literature, we
believe that mechanical debridement in conjunction with
anti-inflammatory agents might give favorable therapeutic
effects in a variety of clinical settings. Previous studies
have reported that aspirin is capable of inhibiting the pro-
duction of TNF-α and IFN-γ [29]. Due to its immuno-
modulatory properties, aspirin has been used to treat
patients with renal transplantation [30]. We have recently
reported that aspirin is capable of reducing the concentra-
tions of TNF-α and IFN-γ and rescuing the osteogenic de-
ficiency of BMSC induced by proinflammatory cytokines
[13]. In addition, studies have been conducted showing
the efficiency of aspirin treatment in MSCs-mediated cell
therapy for treating immune-related disorders, as aspirin
is capable of promoting immunoregulatory properties of
BMMSCs via the 15d-PGJ2/PPARγ/TGF-β1 pathway and
aspirin-pretreated BMMSCs significantly ameliorated dis-
ease activity and colonic inflammation of dextran sodium
sulfate (DSS)-induced experimental colitis in a mice
model [31]. In this study, the concentrations of TNF-α
and IFN-γ in the aspirin treatment group and the concen-
tration of IFN-γ in the BMSC group were significantly de-
creased in the calvarial bone defects, which suggests the
locally transplanted BMSC also have immunoregulatory
properties in local sites.
Conclusions
We have shown in the present study that aspirin-treated
BMSC is capable of promoting calvarial bone regeneration
in a big animal model. We postulated that the local ad-
ministration of aspirin, coupled with MSC, has a twofold
effect on tissue healing; one alleviating inflammatory re-
sponse at sites of disease and the other promoting MSC-
based regenerative capacities (both endogenous and ex-
ogenous MSC) through the suppression of TNF-α and
IFN-γ. Data from a blood biochemistry test demonstrated
no significant changes in animals treated with aspirin-
BMSC. Coupled with the fact that aspirin has been used
as a NSAID for decades with a known side-effect profile,
the local administration of aspirin should possess fewer
safety concerns compared with other strategies, such as
the use of genetically modified stem cells or systemic infu-
sion of regulatory T cells. Future clinical studies may seek
to investigate the potential of aspirin-treated BMSC for
treating bone-related disorders, such as bone fractures,
periodontitis, arthritis, orofacial deformity and immune-
related disorders.
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